These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 31247926)
61. Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials. Maslej MM; Furukawa TA; Cipriani A; Andrews PW; Mulsant BH JAMA Psychiatry; 2020 Jun; 77(6):607-617. PubMed ID: 32074273 [TBL] [Abstract][Full Text] [Related]
62. Recent pharmacologic advances in antidepressant therapy for the elderly. Preskorn SH Am J Med; 1993 May; 94(5A):2S-12S. PubMed ID: 8503477 [TBL] [Abstract][Full Text] [Related]
63. Adherence to, and Persistence of, Antidepressant Therapy in Patients with Major Depressive Disorder: Results from a Population-based Study in Italy. Di Nicola M; Dell'Osso B; Peduto I; Cipelli R; Pugliese AC; Signorelli MS; Ventriglio A; Martinotti G Curr Neuropharmacol; 2023; 21(3):727-739. PubMed ID: 35410606 [TBL] [Abstract][Full Text] [Related]
64. Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up. Peselow ED; Tobia G; Karamians R; Pizano D; IsHak WW Psychiatry Res; 2015 Feb; 225(3):680-6. PubMed ID: 25496869 [TBL] [Abstract][Full Text] [Related]
65. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. Cao B; Zhu J; Zuckerman H; Rosenblat JD; Brietzke E; Pan Z; Subramanieapillai M; Park C; Lee Y; McIntyre RS Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():109-117. PubMed ID: 30611836 [TBL] [Abstract][Full Text] [Related]
67. Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants? Park SH; Wackernah RC; Stimmel GL J Pharm Pract; 2014 Feb; 27(1):71-8. PubMed ID: 24153222 [TBL] [Abstract][Full Text] [Related]
68. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant. Atsou K; Ereshefsky L; Brignone M; Danchenko N; Diamand F; Mucha L; Touya M; Becker R; François C Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):29-42. PubMed ID: 33307885 [No Abstract] [Full Text] [Related]
69. Drug Expenditure, Price, and Utilization in the U.S. Medicaid: A Trend Analysis for SSRI and SNRI Antidepressants from 1991 to 2018. Alrasheed M; Hincapie AL; Guo JJ J Ment Health Policy Econ; 2021 Mar; 24(1):3-11. PubMed ID: 33739932 [TBL] [Abstract][Full Text] [Related]
70. Relative Efficacy and Acceptability of Antidepressant Drugs in Adults With Major Depressive Disorder: Commentary on a Network Meta-Analysis. Andrade C J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29718600 [TBL] [Abstract][Full Text] [Related]
71. Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder. Zhou ZY; Sun S; Chopra P; Zhong Y; Totev T; Signorovitch J J Med Econ; 2015; 18(11):919-29. PubMed ID: 26121061 [TBL] [Abstract][Full Text] [Related]
72. Meta-analytical studies on new antidepressants. Anderson IM Br Med Bull; 2001; 57():161-78. PubMed ID: 11719915 [TBL] [Abstract][Full Text] [Related]
73. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data. Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765 [TBL] [Abstract][Full Text] [Related]
74. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. Thase ME; Danchenko N; Brignone M; Florea I; Diamand F; Jacobsen PL; Vieta E Eur Neuropsychopharmacol; 2017 Aug; 27(8):773-781. PubMed ID: 28663124 [TBL] [Abstract][Full Text] [Related]
75. Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants. Hart XM; Spangemacher M; Defert J; Uchida H; Gründer G Ther Drug Monit; 2024 Apr; 46(2):155-169. PubMed ID: 38287888 [TBL] [Abstract][Full Text] [Related]
76. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Spina E; Santoro V; D'Arrigo C Clin Ther; 2008 Jul; 30(7):1206-27. PubMed ID: 18691982 [TBL] [Abstract][Full Text] [Related]
77. Non-invasive neurostimulation to improve sleep quality and depressive symptoms in patients with major depressive disorder: A meta-analysis of randomized controlled trials. Qiao MX; Yu H; Li T J Psychiatr Res; 2024 Aug; 176():282-292. PubMed ID: 38905761 [TBL] [Abstract][Full Text] [Related]
78. Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study. Kadam RL; Sontakke SD; Tiple P; Motghare VM; Bajait CS; Kalikar MV Indian J Pharmacol; 2020; 52(2):79-85. PubMed ID: 32565594 [TBL] [Abstract][Full Text] [Related]
79. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. Mika J; Zychowska M; Makuch W; Rojewska E; Przewlocka B Pharmacol Rep; 2013; 65(6):1611-21. PubMed ID: 24553009 [TBL] [Abstract][Full Text] [Related]
80. Clinically significant drug interactions with newer antidepressants. Spina E; Trifirò G; Caraci F CNS Drugs; 2012 Jan; 26(1):39-67. PubMed ID: 22171584 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]